Beyond weight-related outcomes, multiple large clinical programmes have demonstrated improvements in: HbA1c fasting glucose waist circumference blood pressure selected cardiovascular outcomes cardiometabolic risk markers Because these findings have been reproduced across numerous independent trials, Semaglutide remains the principal benchmark against which newer dual- and triple-agonist peptides are evaluated
They do not necessarily mean the drug has stopped working
"Metastatic melanomas of unknown primary show better prognosis than those of known primary: a systematic review and meta-analysis of observational studies"
Better Blood Sugar Control: Semaglutide helps regulate blood sugar, reducing the risk of insulin resistance and type 2 diabetes while supporting steady energy throughout the day
Multivariate analysis showed no difference between placebo and liraglutide arms in HbA1c at 6 months (HbA1c:0.2 mmol/mol, 11.3, 11.6, p = 0.98) however, at 12 months HbA1c was significantly higher in the liraglutide arm (HbA1c:10.9 mmol/mol, 1.1, 20.6, p = 0.032)
Hope you find some thing